These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 11959210)

  • 1. Prospective evaluation of a quadruple therapy based on tacrolimus after liver transplantation.
    Lladó L; Figueras J; Ramos E; Lama C; Busquets J; Ibáñez L; Rafecas A; Fabregat J; Torras J; Jaurrieta E
    Transplant Proc; 2002 Feb; 34(1):108. PubMed ID: 11959210
    [No Abstract]   [Full Text] [Related]  

  • 2. Prospective study of a tacrolimus-based quadruple immunosuppressive regimen: evaluation of safety and efficacy.
    Lladó L; Figueras J; Ramos E; Baliellas C; Torras J; Rafecas A; Fabregat J; Lama C; Ibañez L; Jaurrieta E
    Transplant Proc; 2002 Aug; 34(5):1526-8. PubMed ID: 12176468
    [No Abstract]   [Full Text] [Related]  

  • 3. Quadruple versus dual tacrolimus-based induction after liver transplantation: a prospective, randomized trial.
    Langrehr JM; Klupp J; Junge G; Jonas S; Neuhaus R; Bechstein WO; Neuhaus P
    Transplant Proc; 2001 May; 33(3):2330-1. PubMed ID: 11377549
    [No Abstract]   [Full Text] [Related]  

  • 4. Quadruple tacrolimus-based induction therapy including azathioprine and ALG does not significantly improve outcome after liver transplantation when compared with standard induction with tacrolimus and steroids: results of a prospective, randomized trial.
    Neuhaus P; Klupp J; Langrehr JM; Neumann U; Gebhardt A; Pratschke J; Tullius SG; Lohmann R; Radke C; Rayes N; Neuhaus R; Bechstein WO
    Transplantation; 2000 Jun; 69(11):2343-53. PubMed ID: 10868638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Risk and benefit of antibody induction therapy in combination with tacrolimus immunosuppression after liver transplantation.
    Klupp J; Bechstein WO; Pratschke J; Tullius SG; Gebhard A; Lobeck H; Langrehr JM; Neuhaus R; Neuhaus P
    Transplant Proc; 1998 Jun; 30(4):1443-4. PubMed ID: 9636585
    [No Abstract]   [Full Text] [Related]  

  • 6. Tacrolimus-based dual therapy is as efficacious and safe as the conventional tacrolimus-based triple therapy in liver transplantation.
    Salizzoni M; Cavallari A; Risaliti A; Filipponi F; Gerunda GE; Forti D; Fassati LR; Cillo U; Castagneto M; Valente U; Tisone G
    Transplant Proc; 2001 May; 33(3):2258-62. PubMed ID: 11377521
    [No Abstract]   [Full Text] [Related]  

  • 7. A prospective, randomized trial with quadruple versus dual tacrolimus-based induction after liver transplantation.
    Langrehr JM; Klupp J; Pfitzmann R; Neumann U; Lohmann R; Jonas S; Neuhaus R; Steinmüller T; Neuhaus P
    Transplant Proc; 2001; 33(1-2):1520. PubMed ID: 11267404
    [No Abstract]   [Full Text] [Related]  

  • 8. Reduction of early rejection in adult liver transplantation with ATG induction therapy.
    Schulak J; May E; Post A; Fasola C; Mulligan D; Sterling R
    Transplant Proc; 1997; 29(1-2):555-6. PubMed ID: 9123126
    [No Abstract]   [Full Text] [Related]  

  • 9. Chronic rejection after orthotopic liver transplantation is increased under induction therapy with interleukin-2 receptor antibody BT563.
    Langrehr JM; Lohmann R; Raakow R; Jonas S; Klupp J; Bechstein WO; Neuhaus R; Neuhaus P
    Transplant Proc; 2001 May; 33(3):2290-1. PubMed ID: 11377531
    [No Abstract]   [Full Text] [Related]  

  • 10. FK506 for primary and rescue therapy following liver transplantation.
    Platz KP; Mueller AR; Zytowski M; Lobeck H; Neuhaus P
    Transplant Proc; 1998 Jun; 30(4):1409-10. PubMed ID: 9636570
    [No Abstract]   [Full Text] [Related]  

  • 11. Use of FK506 as primary or rescue therapy after liver transplantation in Hong Kong.
    Lo CM; Fan ST; Liu CL; Chan KL; Ng IO; Lai CL; Lau GK; Fung SK; Wong J
    Transplant Proc; 1998 Nov; 30(7):3587-8. PubMed ID: 9838571
    [No Abstract]   [Full Text] [Related]  

  • 12. Early steroid-resistant rejection following orthotopic liver transplantation: new aspects of treatment with FK 506 instead of OKT3?
    Dé P; Bechstein WO; Blumhardt G; Lange D; Schattenfroh N; Neuhaus P
    Transplant Proc; 1993 Aug; 25(4):2693-4. PubMed ID: 7689279
    [No Abstract]   [Full Text] [Related]  

  • 13. Preliminary immunosuppression withdrawal strategies with sirolimus in children with liver transplants.
    Sindhi R; Ganjoo J; McGhee W; Mazariegos G; Reyes J
    Transplant Proc; 2002 Aug; 34(5):1972-3. PubMed ID: 12176651
    [No Abstract]   [Full Text] [Related]  

  • 14. Incidence and outcome of chronic rejection in CyA- and FK 506-treated patients.
    Platz KP; Tullius SG; Mueller AR; Schumacher G; Nüssler N; Neuhaus R; Bechstein WO; Lobeck H; Neuhaus P
    Transplant Proc; 1996 Dec; 28(6):3183-4. PubMed ID: 8962235
    [No Abstract]   [Full Text] [Related]  

  • 15. Tacrolimus and mycophenolate mofetil in cadaveric renal transplant recipients. The European Multicentre Tacrolimus/MMF Study Group.
    Forsythe J
    Transplant Proc; 1999 Nov; 31(7A):69S-71S. PubMed ID: 10576049
    [No Abstract]   [Full Text] [Related]  

  • 16. Immunosuppression with calcineurin inhibitors and polyclonal antibodies in liver transplantation.
    Rafecas A; Lladó L; Albiol MT; Ramos E; Torras J; Fabregat J; Lama C; Busquets J; Ibáñez L; Figueras J; Jaurrieta E
    Transplant Proc; 2002 Feb; 34(1):107. PubMed ID: 11959209
    [No Abstract]   [Full Text] [Related]  

  • 17. A prospective study comparing safety and efficacy of mycophenolate mofetil versus azathioprine in primary liver transplant recipients.
    Fischer L; Sterneck M; Gahlemann CG; Malago M; Rogiers X; Broelsch CE
    Transplant Proc; 2000 Nov; 32(7):2125-7. PubMed ID: 11120098
    [No Abstract]   [Full Text] [Related]  

  • 18. Hepatitis B and C virus-induced diseases and acute rejection after liver transplantation.
    Maggi U; Rossi G; Vannelli A; Caccamo L; Gatti S; Paone G; Reggiani P; Melada E; Latham L; Andreani P; Fassati LR
    Transplant Proc; 1998 Dec; 30(8):3946-7. PubMed ID: 9865255
    [No Abstract]   [Full Text] [Related]  

  • 19. Medium-term outcome of tacrolimus immunosuppression following rejection or graft dysfunction in heart transplant patients.
    Marcus N; Khaghani A; Burke M; Yacoub M; Banner N
    Transplant Proc; 1998 Jun; 30(4):1134-5. PubMed ID: 9636460
    [No Abstract]   [Full Text] [Related]  

  • 20. Conversion to tacrolimus for acute corticosteroid- and antibody-resistant rejection following kidney transplantation.
    Kliem V; Radermacher J; Hiss M; Pethig M; Burg M; Brunkhorst R
    Transplant Proc; 1999 Nov; 31(7A):37S-40S. PubMed ID: 10576041
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.